人源化NBSGW小鼠经骨内递送靶向血小板的因子VIII慢病毒载体
本研究在人源化NBSGW小鼠中经骨内递送靶向血小板的G-F8-LV,验证了该载体可转导自我更新的造血干/祖细胞,并使人血小板持续表达FVIII,从LV处理人源化小鼠分离的人CD34+ HSPCs分化的巨核细胞FVIII表达高达10.2%,载体整合呈多克隆模式,支持该策略长期安全有效并具备临床转化可行性。
要点
- 骨内递送G-F8-LV可转导自我更新的造血干/祖细胞,二次移植可纠正受者血友病A小鼠出血表型。
- G-F8-LV转导人HSPCs后呈巨核细胞特异性表达,整合分析显示多克隆整合模式。
- 人源化NBSGW小鼠经骨内递送G-F8-LV后,人血小板持续表达FVIII,人CD34+ HSPCs分化的巨核细胞FVIII表达高达10.2%。
核心结论
- 骨内递送G-F8-LV基因治疗策略在人源化模型中显示长期安全性和有效性,为临床转化可行性增添证据。
研究设计与样本
- 在人源化NBSGW小鼠中开展骨内递送靶向血小板的G-F8-LV基因转移研究,并评估对人HSPCs的体外转导。
主要发现
- G-F8-LV处理小鼠的HSPCs二次移植可纠正受者血友病A小鼠的出血表型。
- 体外转导人HSPCs后,在优先向巨核细胞系分化时确认巨核细胞特异性基因表达。
- G-F8-LV转导的人细胞中检测到多克隆整合模式。
- 人源化NBSGW小鼠经骨内递送G-F8-LV后,人血小板持续表达FVIII。
- 从LV处理人源化小鼠分离的人CD34+ HSPCs分化的巨核细胞FVIII表达高达10.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously showed that intraosseous (IO) delivery of factor VIII (FVIII, gene F8) lentiviral vector (LV) driven by the megakaryocyte-specific promoter Gp1bα (G-F8-LV) partially corrected the bleeding phenotype in hemophilia A (HemA) mice for up to 5 months. In this study, we further characterized and confirmed the successful transduction of self-regenerating hematopoietic stem and progenitor cells (HSPCs) in treated mice. In addition, secondary transplant of HSPCs isolated from G-F8-LV-treated mice corrected the bleeding phenotype of the recipient HemA mice, indicating the potential of long-term transgene expression following IO-LV therapy. To facilitate the translation of this technology to human applications, we evaluated the safety and efficacy of this gene transfer therapy into human HSPCs. In vitro transduction of human HSPCs by the platelet-targeted G-F8-LV confirmed megakaryocyte-specific gene expression after preferential differentiation of HSPCs to megakaryocyte lineages. Lentiviral integration analysis detected a polyclonal integration pattern in G-F8-LV-transduced human cells, profiling the clinical safety of hemophilia treatment. Most importantly, IO delivery of G-F8-LV to humanized NBSGW mice produced persistent FVIII expression in human platelets after gene therapy, and the megakaryocytes differentiated from human CD34+ HSPCs isolated from LV-treated humanized mice showed up to 10.2% FVIII expression, indicating efficient transduction of self-regenerating human HSPCs. Collectively, these results indicate the long-term safety and efficacy of the IO-LV gene therapy strategy for HemA in a humanized model, adding further evidence to the feasibility of translating this method for clinical applications.
引用
- Joo JH, Wang X, Singh S, et al. Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice. Blood Adv. 2022. PMID: 35849710. doi:10.1182/bloodadvances.2022008079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。